GYNECOLOGIC CANCERS

In an interview with Targeted Oncology, Eirwen M. Miller, MD, discussed the dynamic landscape of ovarian cancer treatment.

The phase 3 LEAP-001 trial did not meet its primary end points of overall survival and progression-free survival.

The FDA has granted priority review to the supplemental biologics application of mirvetuximab soravtansin-gynx for the treatment of patients with platinum-resistant ovarian cancer.

Olvimulogene nanivacirepvec, an oncolytic viral-based therapy, has earned a fast track designation from the FDA in ovarian cancer resistant or refractory to platinum-based chemotherapy.

The combination of tumor-infiltrating lymphocytes and chemotherapy showed a robust response rate and improvements in progression-free survival in a phase 1/2 study.

Findings from a phase 1 trial shows the early promise of an ENB-003 and pembrolizumab regimen for the treatment of platinum refractory or resistant ovarian cancer.

During a Targeted Oncology™ Case-Based Roundtable™ event, Bradley Corr, MD, discussed the use of immune checkpoint inhibitors in patients with advanced endometrial cancer. This is the second of 2 articles based on this event.

Selinexor maintenance therapy shows potential in bettering survival compared with placebo in patients with TP53 wild-type recurrent or advanced endometrial cancer.

Findings from the phase 2 RAMP 201 trial show avutometinib plus defactinib demonstrates robust efficacy in patients with recurrent low-grade serious ovarian cancer.

During a Targeted Oncology™ Case-Based Roundtable™ event, Paul A. DiSilvestro, MD, discussed with participants concerning the management of adverse events in a patient receiving single-agent immune checkpoint inhibitor for advanced mismatch-repair deficient endometrial cancer.

Retrospective data shows that a multidisciplinary surgical approach may improve survival in patients with ovarian cancer.

The combination of dostarlimab and chemotherapy demonstrated meaningful improvements in overall survival for the treatment of primary advanced or recurrent endometrial cancer, according to findings from the phase 3 RUBY trial.

During a Targeted Oncology™ Case-Based Roundtable™ event, David M. O'Malley, MD, discussed with participants their experiences with using PARP inhibitors in patients with advanced ovarian cancer.

In an interview with Targeted Oncology, Brian Slomovitz, MD, details findings from the innovaTV 301 trial investigating tisotumab vedotin for the treatment of recurrent or metastatic cervical cancer.

Tisotumab vedotin-tftv improved survival in patients with recurrent or metastatic cervical cancer with disease progression on doublet chemotherapy.

CLN-619 has emerged for the treatment of advanced solid tumors in the clinical trial setting. Early results are promising, says lead investigator Judy Wang, MD

The first randomized study of immune checkpoint inhibitor therapy in platinum-sensitive ovarian cancer has missed its key end point.

Topline results reported from the UPLIFT trial showed it did not meet its primary end point of objective response rate in the NaPi2b-positive population with ovarian cancer.

Investigators are evaluating the efficacy and safety of selinexor vs placebo when used as a maintenance therapy for patients with p53 wild-type advanced or recurrent endometrial cancer.

Enrollment in the confirmatory phase 3 RAMP 301 study of avutometinib combined with defactinib in low-grade serous ovarian cancer is anticipated to begin in the second half of this year.

In an interview with Targeted Oncology, Bradley J. Monk, MD, FACCOG, FACS, highlighted final results from the phase 3 KEYNOTE-826 trial of pembrolizumab plus chemotherapy vs chemotherapy plus placebo, with or without bevacizumab in persistent, recurrent, or metastatic cervical cancer.

Anna Jo Bodurtha Smith, MD, MPH, MSc, discusses her research on issues facing patients who need care for gynecologic cancers who have private insurance in the United States.

The combination of avutometinib with defactinib elicited high activity in patients with recurrent low-grade serous ovarian cancer, according to data from RAMP 201.

John P. Diaz, MD, discusses how meetings on gynecologic oncology provide advantages for everyday physicians to keep track of the latest updates on the treatment landscape.

Adjuvant chemotherapy did not lead to survival improvements vs standard chemoradiotherapy alone in patients with locally advanced cervical cancer and resulted in more severe adverse events, according to OUTBACK trial data.

Additional findings from KEYNOTE-826 reveal no negative health-related quality-of-life impact when using pembrolizumab plus chemotherapy with or without bevacizumab.

Treatment with ceralasertib with and without olaparib showed promising signals of clinical activity in multiple rare gynecologic cancers, according to findings presented at the European Society for Medical Oncology Gynaecologic Cancers Congress 2023.

Anna Jo Bodurtha Smith, MD, MPH, MSc, discusses why the number of patients with gynecologic cancer that never see a gynecologic oncologist is so high.

Significant rates of homologous recombination deficiency somatic gene mutations were found in patients with uterine serous cancer, resulting in possible implications for future testing and treatment for the patient population, according to the results of a research study.

John P. Diaz, MD, explains the importance of the topics to be discusses at the Miami Cancer Institute Women’s Cancer Symposium on April 21, 2023.